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Introduction: Since	 2009,	 multiple	 randomized	 trials	 have	 shown	 faster	 and	
deeper	 responses	 in	 CML	 patients	 treated	 with	 new-	generation	 TKI	 (NG-	TKI)	
compared	to	those	treated	with	imatinib	(IM).	Are	the	same	results	observed	in	
the	general	population?
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1 	 | 	 INTRODUCTION
The	introduction	of	the	first	tyrosine	kinase	inhibitor	(TKI)	
imatinib	 (IM)	 in	 2001,	 followed	 by	 four	 other	 TKI	 up	 to	






vestigated	 the	 first-	line	 TKI	 treatment	 options	 and	 have	
demonstrated	faster	and	deeper	molecular	response	(MR)	
among	 patients	 treated	 with	 new-	generation	 TKI	 (NG-	
TKI,	i.e.,	dasatinib,	nilotinib,	bosutinib,	or	ponatinib)	than	
those	treated	with	imatinib	(IM).
No	 effect	 on	 overall	 survival	 has	 been	 demonstrated	
due	 to	 the	 low	 number	 of	 events	 in	 randomized	 trials	
during	 the	 follow-	up.	 However,	 a	 recent	 meta-	analysis7	
showed	a	better	short-	term	overall	survival	at	12 months	
after	diagnosis,	with	a	risk	ratio	of	0.57	CI95%	[0.34–	0.95].
Traditional	 thinking	 in	 oncology	 concerning	 the	 re-
sults	of	clinical	trials	tends	to	expect	a	causal	association	













IM	 efficacy	 has	 been	 noted	 with	 patients	 in	 the	 general	
population	compared	to	those	enrolled	in	clinical	trials.12
In	 this	 context,	 describing	 how	 trials	 results	 may	 be	







2 	 | 	 MATERIALS AND METHODS
2.1	 |	 Population
Cases	 were	 identified	 from	 the	 REPIH	 network	 com-
posed	 of	 the	 three	 French	 hematological	 malignancies	
population-	based	 registries:	 the	Gironde	 registry	created	




cal	 regions	 of	 Gironde,	 Calvados,	 Manche,	 Orne,	 and	
Côte-	d’Or.	They	covered	a	source	population	of	3,580,562	
inhabitants	 in	 2016	 (5%	 of	 the	 French	 population).	 The	
National	 Committee	 of	 Registries	 certifies	 their	 quality	
and	completeness	every	4 years.	In	this	study,	all	incident	
cases	 aged	 18	 or	 more	 at	 diagnosis	 were	 included,	 with	
a	CML	BCR-	ABL+	in	chronic	or	accelerated	phase	(ICD-	
O-	3:	 9875/3)	 diagnosed	 between	 1  January	 2006	 and	 31	
December	 2016.	 Atypical	 CML	 (ICD-	O-	3:	 9876/3)	 cases	
were	excluded.
2.2	 |	 Data collection
Trained	 clinical	 research	 associates	 collected	 data	 from	
electronic	 medical	 reports	 in	 a	 standardized	 case	 report	
form.	 The	 phase	 at	 diagnosis	 was	 defined	 according	 to	
ELN	2013	criteria.13	The	EUTOS	long-	term	survival	score	
(ELTS)	 and	 Sokal	 score	 were	 then	 calculated.	 First-	line	
was	defined	as	the	first	treatment	for	CML	given	after	di-
agnosis.	A	major	molecular	response	(MMR)	was	defined	
according	 to	 ELN	 2013	 criteria	 when	 original	 reports	 of	
bcr-	abl/abl	 value	 were	 found	 in	 medical	 files,	 or	 physi-
cian's	 interpretation	 of	 the	 bcr-	abl	 result	 as	 recorded	 in	
the	patient's	file	if	not.	As	molecular	monitoring	was	per-
formed	in	limited	number	of	university	labs	and	because	
of	 the	STIC	program	started	 in	France	 in	2005,	we	have	





whichever	 event	 came	 first.	 Times	 to	 MMR	 and	 other	
events	 were	 calculated	 in	 months	 from	 TKI	 initiation.	
Patients	not	receiving	first-	line	TKI	treatment	or	 treated	
with	hydroxyurea	for	more	than	3 months	were	excluded.	
Short	 pre-	treatment	 (<3  months)	 with	 interferon	 alpha	
or	 hydroxyurea	 was	 allowed.	 Treatment	 dosage	 was	 not	
collected	in	the	study	and	data	were	most	likely	not	avail-




or	 not	 with	 other	 treatments	 (i.e.,	 interferon),	 and	 the	
“new-	generation	 group”	 (NG-	TKI)	 for	 patients	 treated	
with	dasatinib,	ponatinib,	bosutinib,	or	nilotinib.	Age	was	
divided	into	three	categories	(<30 years	old,	30–	65 years	
old,	 and	 >65  years	 old),	 with	 the	 Eastern	 Cooperative	










optimal	 response”	 (ELN	 2013  grouping	 of	 “sub-	optimal	


























tional	 clinical	 trial,	 care	 facilities	 where	 the	 patient	 was	
first	treated,	ECOG,	ACE-	27,	Sokal	score	(preferred	over	
ELTS	score	as	its	introduction	in	2016	did	not	match	our	












cal	 trial.	To	 facilitate	 interpretation	of	 the	covariable	ef-
fect	 on	 the	 outcome,	 the	 cumulative	 incidence	 of	 MMR	
in	first-	line	therapy	and	on	competitive	events	(first-	line	
switch	 or	 death)	 for	 follow-	up	 was	 plotted	 using	 the	
Aalen–	Johansen	estimator.18




was	 designed	 to	 highlight	 patient	 distribution	 according	
to	 their	 clinical	 pathways	 based	 on	 chosen	 characteris-
tics:	that	is,	where	patients	were	first	treated,	if	they	were	
















Enrollment in clinical trial
Years of diagnosis
Karyotype abnormality
CML phase at diagnosis
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in	the	diagram,	with	the	columns	divided	into	blocks	cor-
responding	to	each	characteristic's	category.	Each	column	
is	horizontally	 linked	by	 flows	and	each	 flow	represents	
a	unique	and	specific	clinical	pathway.	The	height	of	the	
block	and	the	size	of	the	flow	reflect	the	count	of	patients:	
the	 larger	 they	 are,	 the	 more	 numerous	 the	 patients.	 A	
darker	color	 indicates	 the	vital	 status	at	endpoint	 (dark:	
patients	dead	at	endpoint	date,	light:	patients	alive	at	end-





Analyses	 were	 performed	 on	 R	 3.6.3	 with	 RStudio	
1.2.5033,	the	following	R	packages	were	used:	mice,	sur-
vival,	flextable,	survminer,	ggalluvial,	and	tidyverse.
3 	 | 	 RESULTS
3.1	 |	 Population
From	 2006	 to	 2016,	 521	 CML	 cases	 in	 chronic	 phase	 or	
accelerated	 phase	 were	 identified.	 In	 total,	 507	 were	 in-
cluded	 in	 the	 analysis,	 while	 14	 were	 excluded	 as	 they	
were	not	treated	with	a	TKI	in	the	first-	line	(nine	received	
hydroxyurea	 and	 five	 were	 not	 treated	 due	 to	 very	 old	
age,	 severe	 co-	morbidities,	 or	 CML	 in	 transformation).	








Compared	 to	 IM,	patients	 in	 the	NG-	TKI	group	were	















enrolled.	 Patients	 treated	 with	 NG-	TKI	 achieved	 MMR	











Following	 adjustment	 on	 the	 potential	 confounding	
factors	identified,	patients	in	the	NG-	TKI	group	were	sig-
nificantly	 more	 likely	 to	 achieve	 MMR	 during	 first-	line	
treatment	 than	 those	 in	 the	 IM	 group	 (HR:	 1.88	 CI95%	
[1.35–	2.61])	 (Table  3).	 After	 visual	 verification,	 non-	
linearity	of	hazard	risk	assumption	over	time	was	rejected	
for	all	variables.	The	results	were	 in	 line	with	 those	dis-
played	by	the	cumulative	incidence	analyses	(Figure 2).
3.3	 |	 Switching and discontinuation of 














30  years.	 They	 had	 higher	 risk	 scores	 (especially	 ELTS	





39%	 (26/66)	 had	 not	 achieved	 MMR,	 all	 but	 one	 were	
treated	with	IM,	and	42%	(11/26)	were	treated	in	GH	or	
PC	 (vs.	 23%	 in	 the	 study	 population).	 Competitive	 risk	
analysis	 on	 TKI	 generation	 effect	 on	 survival	 in	 first-	
line	therapy	did	not	converge,	as	events	were	too	few	(26	
events	 and	 all	 but	 one	 in	 the	 IM	 group),	 thus	 result	 in	
this	setting	was	not	available	(Table 3).
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To	illustrate	patients’	pathways	and	visualize	their	char-
acteristics,	 an	 alluvial	 plot	 was	 drawn	 according	 to:	 the	
first	care	facility,	whether	they	were	enrolled	in	a	clinical	
trial,	 first-	line	 TKI	 generation,	 whether	 they	 achieved	













<30 years 13	(3.4) 7	(5.9) 20	(3.9)
30–	65 years 185	(47.6) 92	(77.3) 277	(54.7)
>65 years 190	(49.0) 20	(16.8) 210	(41.4)

















Chronic 371	(95.6) 114	(95.8) 485	(95.7)
Accelerate 17	(4.4) 5	(4.2) 22	(4.3)
Sokal	score,	n	(%)
Low-	risk 100	(26.7) 49	(42.2) 149	(30.3)
Intermediate-	risk 187	(49.8) 42	(36.2) 229	(46.7)
High-	risk 88	(23.5) 25	(21.6) 113	(23.0)
Missing 13	(—	) 3	(—	) 16	(—	)
EUTOS	long-	term	survival	(ELTS)	score,	n	(%)
Low-	risk 177	(47.2) 76	(65.5) 253	(51.5)
Intermediate-	risk 138	(36.8) 26	(22.4) 164	(33.4)
High-	risk 60	(16.0) 14	(12.1) 74	(15.1)
Missing 13	(—	) 3	(—	) 16	(—	)
ECOG,	n	(%)
0–	1 313	(91.5) 107	(95.5) 420	(92.5)
2–	3–	4 29	(8.5) 5	(4.5) 34	(7.5)
Missing 46	(—	) 7	(—	) 53	(—	)
Adult	comorbidity	evaluation	(ACE-	27),	n	(%)
None 119	(30.7) 70	(58.8) 189	(37.4)
Mild 163	(42.1) 38	(31.9) 201	(39.7)
Moderate	to	severe 105	(27.1) 11	(9.2) 116	(22.9)
Missing 1	(—	) 0	(—	) 1	(—	)
Deceased	at	30 June	2018,	n	(%) 104	(26.8) 5	(4.2) 109	(21.5)
T A B L E  1 	 Descriptive	table	of	the	total	
population	according	to	TKI	generation	in	
first-	line	(n = 507)
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More	 generally,	 the	 diagram	 illustrates	 the	 different	
characteristics	 of	 deceased	 patients.	 It	 shows	 they	 were	
more	 frequently	 treated	 in	 GH	 or	 PC	 than	 TH	 or	 CCC,	
were	not	enrolled	in	a	clinical	trial,	were	treated	in	first-	
line	 with	 IM	 (all	 but	 5),	 and	 had	 equivalently	 achieved	
MMR	or	switched	treatment	line.	Deceased	patients	that	
T A B L E  2 	 Descriptive	table	of	the	population	according	to	enrollment	in	a	clinical	trial	at	diagnosis	(n = 506,	one	missing	data	for	a	
patient)
Characteristics Not enrolled in a clinical trial (n = 392)
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did	not	switch	 to	another	 line	can	be	dichotomized	 into	
groups	 of	 patients	 that	 achieved	 MMR	 (40/66)	 or	 not	
(26/66).	 Their	 median	 time	 from	 treatment	 initiation	 to	







patients	 switched	 proportionately	 more	 frequently	 from	
first-	line	due	to	a	non-	optimal	response.
Regarding	 the	 group	 of	 patients	 that	 switched	 to	
second-	line	(n = 203),	the	main	reason	for	switching	was	
a	non-	optimal	response	(56%,	114/203),	 followed	by	 tox-















Among	 the	 group	 of	 patients	 (n  =  20)	 that	 stopped	
their	 first-	line	 treatment	without	 switching,	80%	 (16/20)	
were	 treated	 with	 IM,	 63%	 (10/16)	 stopped	 the	 first-	line	















[1.35–	2.61]).	 This	 result	 is	 consistent	 with	 clinical	 trial	








Cause- specific hazard ratio
MMR Line switch Death
NG-	TKI	versus	IM 1.88	[1.35–	2.61] 1.14	[0.68–	1.90] —	a	
aModel	did	not	converge.













MMR 1st line switch Death
















































































T A B L E  4 	 Characteristics	of	the	
population	according	to	their	vital	status	
at	the	end	of	follow-	up	(n = 507)
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Those	differences	described	could	partly	explain	char-
acteristics	dissimilarity	observed	among	NG-	TKI	patients	
since	50%	of	 them	were	 included	in	a	clinical	 trial	com-
pared	to	14%	for	IM	patients.	Another	explanation	could	
be	the	availability	of	the	treatment	at	the	time	of	diagno-
sis:	no	NG-	TKI	 in	 first-	line	were	available	 in	France	be-










diagnosis	 was	 younger	 than	 in	 our	 population	 and	 with	
NG-	TKI	patients	younger	than	IM	patients.
It	was	observed	that	41%	of	patients	treated	with	IM	in	
first-	line	 switched	 to	 a	 second-	line.	This	 proportion	 was	





















study	 also	 unexpectedly	 described	 some	 non-	MMR	 de-
ceased	 patients	 who	 had	 not	 switched	 to	 a	 second-	line	
after	1 year	of	treatment.	This	may	be	explained	by	prac-




been	 able	 to	 follow	 treatment	 guidelines.27	 In	 addition,	
proportionally	more	patients	died	in	GH	or	private	clinics	










































the	 literature,28,29	 confirming	 the	 choice	 of	 MMR	 as	 the	
main	outcome	criterion	for	our	study.














generation	 on	 treatment	 switch	 before	 MMR	 or	 death.	
Nevertheless,	 the	 second-	generation	 TKI	 appears	 to	 be	
more	effective,	but	also	more	toxic	 in	a	 first-	line	context	




and	assessing	 the	different	 treatment	effects	 in	 the	popu-
lation	reached.	It	was	not	a	substitute	for	rigorous	clinical	
trials	 and	 did	 not	 estimate	 the	 difference	 in	 efficacy	 be-
tween	 the	TKI	generations.	The	study	has	both	strengths	
and	 limitations.	 Its	 major	 strength	 is	 its	 comprehensive-



















































Data	 collection	 and	 analyses	 were	 performed	 within	
French	National	Commission	on	Informatics	and	Liberty	
(CNIL)	authorization	scope	of	the	three	registries	partici-
pating	 in	 the	 study	 (Registre des Hémopathies Malignes 
de Côte d’Or: CNIL no 97.013,	 Registre des hémopathies 
malignes de la Gironde: CNIL no 90.3445,	 and	 Registre 
Régional des Hémopathies Malignes de Basse- Normandie: 
CNIL no 1276682).
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